A detailed history of Nuveen Asset Management, LLC transactions in Erasca, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 483,583 shares of ERAS stock, worth $942,986. This represents 0.0% of its overall portfolio holdings.

Number of Shares
483,583
Previous 1,172,606 58.76%
Holding current value
$942,986
Previous $2.77 Million 52.29%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.17 - $3.28 $1.5 Million - $2.26 Million
-689,023 Reduced 58.76%
483,583 $1.32 Million
Q2 2024

Aug 09, 2024

BUY
$1.79 - $2.63 $863,504 - $1.27 Million
482,405 Added 69.89%
1,172,606 $2.77 Million
Q1 2024

May 13, 2024

SELL
$1.67 - $2.55 $851,284 - $1.3 Million
-509,751 Reduced 42.48%
690,201 $1.42 Million
Q4 2023

Feb 14, 2024

BUY
$1.67 - $2.49 $3,360 - $5,009
2,012 Added 0.17%
1,199,952 $2.56 Million
Q3 2023

Nov 14, 2023

BUY
$1.97 - $2.91 $35,909 - $53,043
18,228 Added 1.55%
1,197,940 $2.36 Million
Q2 2023

Aug 14, 2023

BUY
$2.57 - $3.3 $1.2 Million - $1.55 Million
468,305 Added 65.83%
1,179,712 $3.26 Million
Q1 2023

May 15, 2023

BUY
$2.74 - $4.44 $962,581 - $1.56 Million
351,307 Added 97.56%
711,407 $2.14 Million
Q4 2022

Feb 14, 2023

BUY
$3.89 - $8.57 $340,059 - $749,180
87,419 Added 32.06%
360,100 $1.55 Million
Q3 2022

Nov 14, 2022

SELL
$5.82 - $10.68 $41,839 - $76,778
-7,189 Reduced 2.57%
272,681 $2.13 Million
Q2 2022

Aug 15, 2022

BUY
$4.58 - $8.72 $168,736 - $321,262
36,842 Added 15.16%
279,870 $1.56 Million
Q1 2022

May 16, 2022

BUY
$8.6 - $15.48 $1.84 Million - $3.3 Million
213,389 Added 719.96%
243,028 $2.4 Million
Q4 2021

Feb 14, 2022

SELL
$12.51 - $22.75 $164,356 - $298,889
-13,138 Reduced 30.71%
29,639 $384,000
Q3 2021

Nov 12, 2021

BUY
$17.43 - $24.34 $745,603 - $1.04 Million
42,777 New
42,777 $908,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $238M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.